5-氨基-2-溴苯甲酸 | 2840-02-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-2-溴苯甲酸
• 中文别名: 2-溴-5-氨基苯甲酸
• 英文名称: 5-amino-2-bromobenzoic acid
• CAS: 2840-02-0
• 化学式: C₇H₆BrNO₂
• mdl: MFCD07368968
• 分子量: 216.034
• InChiKey: FEXDUVBQBNYSQV-UHFFFAOYSA-N

物化性质

• 熔点：
  171-179 °C
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37
• 危险类别码：
  R22
• WGK Germany：
  3
• 危险品运输编号：
  UN 2811 6.1/PG 3
• 海关编码：
  2922499990
• 危险标志：
  GHS06
• 危险性描述：
  H301,H315,H319,H335
• 危险性防范说明：
  P261,P301 + P310,P305 + P351 + P338
• 储存条件：
  室温

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Amino-2-bromobenzoic acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 2840-02-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22, R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C7H6BrNO2
Molecular Weight : 216,03 g/mol
CAS-No. : 2840-02-0
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Amino-2-bromobenzoic acid
CAS-No. 2840-02-0 Acute Tox. 3; Skin Irrit. 2; Eye <= 100 %
Irrit. 2; STOT SE 3; H301,
H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Amino-2-bromobenzoic acid
CAS-No. 2840-02-0 Xn, R22 - R36/37/38 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 171 - 179 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,774
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx),
Hydrogen bromide gas
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. The
preceding data, or interpretation of data, was determined using Quantitative Structure Activity Relationship
(QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (5-Amino-2-bromobenzoic acid)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (5-Amino-2-bromobenzoic acid)
IATA: Toxic solid, organic, n.o.s. (5-Amino-2-bromobenzoic acid)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-2-溴苯甲酸 在 连二磷酸 作用下， 生成 2-溴苯甲酸
  参考文献：
  名称：

  Raiford; Oberst, American Journal of Pharmacy and the Sciences Supporting Public Health (1937-1978), 1935, vol. 107, p. 242

  摘要：

  DOI：
• 作为产物：
  描述：

  间氨基苯甲酸 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 以78%的产率得到5-氨基-2-溴苯甲酸
  参考文献：
  名称：

  3-HYDROXY-6H-BENZO [C] CHROMENE-6-ONE DERIVATIVE AND MANUFACTURING METHOD THEREOF

  摘要：

  一种制造化合物或其盐的方法，其特征在于使具有以下式（I）表达的化合物或其盐与具有以下式（II）表达的化合物或其盐在碳酸盐和铜盐的存在下或在氢氧化物、碳酸盐和铜盐的存在下发生反应，所得产物表达式如下（III）。

  公开号：

  US20130310576A1

文献信息

• Supramolecular Control of Selectivity in Hydroformylation of Vinyl Arenes: Easy Access to Valuable β-Aldehyde Intermediates
  作者：Paweł Dydio、Joost N. H. Reek

  DOI：10.1002/anie.201209582

  日期：2013.4.2

  flow! A rationally designed regioselective hydroformylation catalyst, [Rh/L], in which noncovalent ligand–substrate interactions allow the unprecedented reversal of selectivity from the typical α‐aldehyde to the otherwise unfavored product β‐aldehyde, is reported. This catalytic system opens up novel and sustainable synthetic pathways to important intermediates for the fine‐chemicals industry.

  逆流而上！据报道，一种合理设计的区域选择性加氢甲酰化催化剂[Rh / L]，其中非共价配体-底物的相互作用使选择性从典型的α-醛到其他不利的产物β-醛发生了前所未有的逆转。该催化体系为精细化工行业的重要中间体开辟了新的，可持续的合成途径。
• Selenium-Catalyzed C(sp³)H Acyloxylation: Application in the Expedient Synthesis of Isobenzofuranones
  作者：Felix Krätzschmar、Martin Kaßel、Daniel Delony、Alexander Breder

  DOI：10.1002/chem.201406290

  日期：2015.5.4

  Oxidative Se‐catalyzed C(sp3)H bond acyloxylation has been used to construct a diverse array of isobenzofuranones from simple ortho‐allyl benzoic acid derivatives. The synthetic procedure employs mild reaction conditions and gives high chemoselectivity enabled by an inexpensive organodiselane catalyst. The presented approach offers a new synthetic pathway toward the core structures of phthalide natural

  氧化的Se催化的C（sp 3）H键酰氧基化已被用来从简单的邻烯丙基苯甲酸衍生物构造出各种各样的异苯并呋喃酮。合成过程采用温和的反应条件，并通过廉价的有机二硒烷催化剂实现了高化学选择性。提出的方法为邻苯二甲酰亚胺天然产物的核心结构提供了一条新的合成途径。
• [EN] CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR<br/>[FR] AMIDES AROMATIQUES D'ACIDE CARBOXYLIQUE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA BRADYKININE B1
  申请人：BAYER PHARMA AG

  公开号：WO2018114786A1

  公开（公告）日：2018-06-28

  The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）所述和定义的羧酸芳香酰胺化合物，以及包含该化合物的药物组合物和药物组合物的用途，用于制造用作治疗或预防疾病的药物组合物，作为唯一药剂或与其他活性成分组合使用。
• Extending the Structure–Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist
  作者：Daniel Merk、Christina Lamers、Khalil Ahmad、Roberto Carrasco Gomez、Gisbert Schneider、Dieter Steinhilber、Manfred Schubert-Zsilavecz

  DOI：10.1021/jm500937v

  日期：2014.10.9

  The ligand activated transcription factor nuclear farnesoid X receptor (FXR) is involved as a regulator in many metabolic pathways including bile acid and glucose homeostasis. Therefore, pharmacological activation of FXR seems a valuable therapeutic approach for several conditions including metabolic diseases linked to insulin resistance, liver disorders such as primary biliary cirrhosis or nonalcoholic

  配体激活的转录因子核法呢素X受体（FXR）作为调节剂参与了许多代谢途径，包括胆汁酸和葡萄糖稳态。因此，对于多种疾病，包括与胰岛素抵抗相关的代谢性疾病，肝脏疾病（如原发性胆汁性肝硬化或非酒精性脂肪性肝炎）和某些形式的癌症，FXR的药理激活似乎是一种有价值的治疗方法。但是，可用的FXR激动剂会完全激活受体，这在较长的时间段内可能是不利的。因此，长期治疗代谢紊乱需要部分FXR激活剂。我们在这里报告了作为FXR调节剂的邻氨基苯甲酸衍生物的SAR以及化合物51的开发，合成和表征，它是一种高效的报告基因部分FXR激动剂，在EC 50值为8±3 nM，在肝细胞中的mRNA水平上。
• [EN] 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES<br/>[FR] DERIVES DE 1-(2-AMINO-BENZOL)-PIPERAZINE EN TANT QU'INHIBITEURS DE L'ABSORPTION DU GLYCOCOLLE POUR TRAITER DES PSYCHOSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005023260A1

  公开（公告）日：2005-03-17

  A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  具有式（I）的化合物，其中取代基如权利要求1中所述，用于治疗精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及认知过程受损的其他疾病，如注意力缺陷障碍或阿尔茨海默病。